Enliven Therapeutics, Inc.
NASDAQELVN reports after the close today having gained 20% over the past month — a stock re-rating that has run well ahead of the broader small-cap biotech tape and sets a high bar for the print. The analyst community has been uniformly bullish in the run-up. Goldman Sachs lifted its target to $67 on July 21 while reiterating Buy — the most notable move from a bellwether firm. Stifel and…
ELVN cost to borrow surges to 1.22%, up 127% in one week, as availability plummets to 1,812% of short interest.
Snapshot as of 20 Sept 2026
ELVN reports after the close today having gained 20% over the past month — a stock re-rating that has run well ahead of the broader small-cap biotech tape and sets a high bar for the print. The analyst community has…
Enliven Therapeutics heads into July with analyst conviction rising sharply on one side and a quiet but steady rebuild in short positioning on the other — a split that makes the setup more charged than the stock's…
Enliven Therapeutics enters its June 9 earnings call in an uncomfortable spot: the stock has shed 16.5% over the past week and 15% over the past month, closing at $35.52, while Wall Street has just sharply lifted its…
Enliven Therapeutics heads into its May 11 earnings release carrying the fingerprints of a short-side exodus — but options traders remain more defensively positioned than usual. Short sellers have been quietly exiting.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELVN — free to start on ORTEX.
Sign up for free →Open ELVN on ORTEX